Overview

Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Cognitive training is moderately effective at reducing symptoms and improving life function in schizophrenia patients. The present application develops a strategy for increasing the effectiveness of cognitive training through the use of pro-cognitive medications. Specific biomarkers will be studied that identify patients most sensitive to these pro-cognitive medications, to test the feasibility of using these biomarkers in a large clinical trial of medication-enhanced cognitive training in schizophrenia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Diego
Treatments:
Memantine